In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low- and middle-income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.
“Oncologists and hematologists from these leading cancer centers are the true heroes of our humanitarian treatment access success story,” said Pat Garcia-Gonzalez, CEO of The Max Foundation. “Their dedication to their patients and commitment to our partnership allows us to prevent unnecessary and premature cancer deaths. Working in a challenging environment, their personal contributions go well beyond treatment management and inspire us to do our best to support their patients’ needs.”
Dr. Damira Bayzakova, Kyrgyzstan, adds that “Providing lifesaving treatment to one patient does not save the life of one patient – it saves the lives of the dozens of small children and elderly family members who depend on that patient for their survival.”
The Max Foundation aims to sign collaboration agreements with a total of 350 hematologists and oncologists from more than 70 countries in 2017.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.
